Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study by Malmborg, Morten et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Incidence of new onset cancer in patients with a myocardial infarction - a nationwide
cohort study
Malmborg, Morten; Christiansen, Christine Benn; Schmiegelow, Michelle D; Torp-Pedersen,
Christian; Gislason, Gunnar; Schou, Morten
Published in:
BMC Cardiovascular Disorders
DOI:
10.1186/s12872-018-0932-z
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Malmborg, M., Christiansen, C. B., Schmiegelow, M. D., Torp-Pedersen, C., Gislason, G., & Schou, M. (2018).
Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study. BMC
Cardiovascular Disorders, 18(1), 1-9. [198]. https://doi.org/10.1186/s12872-018-0932-z
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
Incidence of new onset cancer in patients
with a myocardial infarction – a nationwide
cohort study
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Gunnar Gislason1,4 and Morten Schou1
Abstract
Background: Few studies have suggested that patients with myocardial infarction (MI) may be at increased risk of
cancer, but further large register-based studies are needed to evaluate this subject. The aim of this study was to
assess the incident rates of cancer and death by history of MI, and whether an MI is independently associated with
cancer in a large cohort study.
Method: All Danish residents aged 30–99 in 1996 without prior cancer or MI were included and were followed
until 2012. Patients were grouped according to incident MI during follow-up. Incidence rates (IR) of cancer and
death in individuals with and without MI and incidence rate ratios (IRR, using multivariable Poisson regression
analyses) of cancer associated with an MI were calculated.
Results: Of 2,871,168 individuals, 122,275 developed an MI during follow-up, 11,375 subsequently developed cancer
(9.3%, IR 19.1/1000 person-years) and 65,225 died (53.3%, IR 106.0/1000 person-years). In the reference population,
372,397 developed cancer (13.0%, IR 9.3/1000 person-years) and 753,767 died (26.3%, IR 18.2/1000 person-years).
Compared to the reference population, higher IRs of cancer and death were observed in all age groups (30–54,
55–69 and 70–99 years) and time since an MI (0–1, 1–5 and 5–17 years) in the MI population. MI was associated
with an increased risk of overall cancer (IRR 1.14, 95% CI 1.10–1.19) after adjusting for age, sex and calendar year,
also when additionally adjusting for chronic obstructive pulmonary disease, hypertension, dyslipidemia, diabetes
and socioeconomic status (IRR 1.08, 95% CI 1.03–1.13), but not after further adjustment for the first 6 months
post-MI (IRR 1.00, 95% CI 0.96–1.05).
Conclusion: Patients after an MI have increased incidence of cancer, which may be explained by mutual risk, occult
cancers and increased surveillance. Focus on risk factor management to reduce cancer and MI is warranted.
Keywords: Myocardial infarction, Cancer, Epidemiology, Patient registries
Background
Ischemic heart disease and cancer are the two primary
causes of death worldwide. Denmark is the only country
in Europe where cancer has surpassed cardiovascular
disease as the primary cause of death in both women
and men [1, 2]. Due to improved management of MI
patients such as increased use of prophylactic
pharmacotherapy and more available use of cardiac
revascularization, mortality rates after an MI,
short-term as well as long-term, have decreased over
the past decades [3, 4]. Consequently, the increasing
number of MI survivors are at risk of dying from
non-cardiac competing causes of death, cancer in
particular, as has previously been demonstrated for
STEMI patients following percutaneous coronary
intervention [5, 6] and among patients with heart
failure [7].
The association between cancer and MI is biologically
plausible due to shared pathogenesis such as oxidative
stress [8, 9] and shared risk factors (i.e. tobacco, alcohol
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consumption, obesity, physical inactivity, unhealthy food
consumption and metabolic disorders such as hyperten-
sion, dyslipidemia and diabetes) [10, 11]. Additionally,
occult cancers are prothrombotic [12] and increase the
risk of MI [13]. However, the risk of cancer following an
MI remains scarcely investigated. Although, three stud-
ies have found an increased risk of cancer after an MI,
[14–16] of which the two oldest studies found an in-
creased risk of predominantly tobacco-related cancers,
none of them have taken the high mortality after an MI
into account.
To evaluate the association between an MI and cancer
there are a number of caveats that need to be accounted
for, which involves analyses of competing risk and
surveillance bias. Due to high mortality rates after an
MI, an independent association between an MI and can-
cer may, therefore, have been overlooked in previous
studies, and the possible association calls for further
investigations.
Therefore, the aims of this study were to assess the in-
cident rates of cancer and death by history of MI, as well
as the association between an MI and new onset cancer
in patients surviving a first-time MI compared with the
reference population.
Methods
Data sources
All residents in Denmark receive a unique and perman-
ent civil registration number at birth or immigration that
enables linkage between nationwide registers at an indi-
vidual level. Data for this study were obtained from four
large Danish registries: The Danish Civil Registration
System registry, the Danish National Patient Registry
(NPR), the National Causes of Death Registry and the
Danish National Prescription Registry. From the Danish
Civil Registration System registry we obtained informa-
tion on sex, date of birth and vital status (recorded
within two weeks from the event), whereas causes of
death were obtained from the National Causes of Death
Registry and classified according to the International
Classification of Diseases (ICD)-8 until 1993 and ICD-10
from 1994 and onwards. From the National Patient
Registry we achieved information on all hospital admis-
sions since 1977 with diagnoses coded according to the
ICD system. Lastly, we obtained information on all
claimed prescriptions in Denmark since 1995 from the
Danish National Prescription Registry according to the
Anatomical Therapeutic Chemical (ATC).
Study population
Our study population comprised all individuals aged
30–99 years residing in Denmark on 1 January 1996.
Patients with a first-time diagnosis of MI (ICD-8 code
410, ICD-10 codes I21–22) or first-time cancer
(ICD-8 codes 140–209, ICD-10 codes C00–96) prior
to 1 January 1996 were excluded, as were individuals
who had a first-time diagnosis of cancer and MI on
the same day during follow-up. Patients were grouped
according to incident MI during follow-up. Thus, the
reference population comprised the total Danish
population without prior MI or cancer in 01 January
1996, and the MI population comprised those individ-
uals from the reference population who developed an
MI during follow-up without prior cancer at the time
of an MI. The ICD-8 diagnosis of an MI in the NPR
has been validated in the Danish MONICA (Monitor-
ing Trends and Determinants in Cardiovascular
Disease) study with a positive predictive value of
93.5% for definite or possible MI and a sensitivity of
92.8% for definite MI [17]. The ICD-10 diagnosis of
MI as well as cancer in the NPR has been validated
with a positive predictive value of 98% and 98–100%,
respectively [18, 19].
The following comorbidities were identified: hyperten-
sion, dyslipidemia, diabetes and chronic obstructive
pulmonary disease (ICD-8 codes 490–492 and ICD-10
codes J42, J44). Hypertension was defined as combin-
ation treatment with at least two classes of antihy-
pertensive drugs within 90 days, as previously validated
[20]. Diabetes mellitus was defined as the use of
glucose-lowering medication (ATC A10), [21] and
dyslipidemia as claimed prescriptions of lipid modifying
agents (C10A). Medications at baseline were defined as
dispensed prescriptions prior to inclusion for aspirin
(B01AC06 and N02BA01), renin-angiotensin system
inhibitors (C09AA, C09BA, C09BB, C09CA, C09DA,
C09DB, C09XA02 and C09XA52), calcium channel
blockers (C08, C07F, C09BB and C09DB), beta-blockers
(ATC C07A-C07D and C07F) and statins (C10AA).
Socioeconomic status was identified as educational at-
tainment and categorized as follows: (1) Basic education
(primary, lower secondary); (2) upper secondary (general
secondary, technical secondary); (3) vocational; (4) short
or medium length higher education (Academy Profession
Degree, Professional Bachelor’s Degree, university
Bachelor’s Degree); (5) Master’s Degree or Ph.D. Degree;
(6) unknown.
Outcomes
The primary outcome was any incident cancer reported
in the NPR or as cause of death (ICD-10 codes C00–96).
From the NPR we also obtained information on the five
most common types of cancer types according to the
Association of Nordic Cancer Registries: Lung cancer
including trachea and bronchus (C33–34), colorectal
(C18–20), breast (C50), prostate (C61) and lower
urinary tract cancer (LUT, ureters, bladder and
urethra) (C66–68.0).
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Statistics
The reference population was followed from 1 January
1996 until an MI event, death, cancer event, emigration,
age 100 or 31 December 2012, whichever came first, and
the MI population was followed from diagnosis of MI
until death, cancer event, emigration, age 100 or 31
December 2012, whichever came first.
We calculated crude incidence rates (IR) of cancer
and death stratified by age groups (30–54, 55–69 and
70–99 years of age) and time since a diagnosis of MI
(0–1, 1–5 and 5–17 years post-MI). We further ex-
amined the cumulative incidence of cancer according
to history of an MI and age groups in which the
competing risk of death was taken into account. We
used a 0–1-2 outcome variable to determine those
with no cancer diagnosis or date of death, those who
received a cancer diagnosis or died from cancer, and
those who died from other causes than cancer,
respectively.
We used time-dependent multivariable Poisson regres-
sion models to examine the incidence rate ratios (IRR)
of cancer associated with an MI, as previously performed
[22]. Each individual contributed with disease-free ex-
posure time until date of diagnosis of MI, and from this
day onwards with time exposed for the disease. We used
the lexis-macro [23] prior to all analyses to create three
time scales: age (bands were split into 2-year intervals),
calendar year (1-year intervals since January 1, 1996)
and time following MI (1, 3, 6 and 12 months and every
year hereafter). Dichotomous variables were created for
MI (MI/no MI), and age was calculated at the beginning
of each interval. Prior to the date of their first MI, indi-
viduals contributed risk time to the reference popula-
tion, which in all analyses consisted of the general
Danish population without MI.
We assessed the associations between MI and subse-
quent risk of cancer by two approaches. In the main
analyses, we examined the association between MI
and subsequent cancer risk according to time follow-
ing MI (adjusted for sex, age and calendar year).
Secondly, we explored the IRRs of cancer associated
with MI stratified by age compared with risk of
cancer in the reference population (adjusted for sex
and calendar year). The same approach was used for
the five selected types of cancers. All statistical
analyses were conducted using SAS, version 9.4 (SAS
institute, Cary, NC, USA).
Sensitivity analyses
In accordance with our hypothesis, increased risk of
cancer in MI patients could be confounded by shared
risk factors or comorbidities that are markers of risk fac-
tors [24]. We, therefore, conducted sensitivity analyses,
in which we adjusted for dyslipidemia, hypertension,
diabetes mellitus, chronic obstructive pulmonary disease
and socioeconomic status.
The same analyses were performed without the first
six months following an MI, as this period of time is
most likely to be affected by surveillance bias.
Results
Patient selection and study population characteristics
Following exclusion of individuals according to the
pre-defined criteria, the final population comprised
2,871,168 individuals without prior MI or cancer, and
122,275 individuals subsequently developed an MI
(Fig. 1). At baseline, both men and women had a median
age of about 50 years, whereas women were about
9 years older than men at time of first MI (Table 1).
Individuals with MI were more often men and had a
higher proportion of chronic obstructive pulmonary
disease, hypertension, dyslipidemia and diabetes than the
reference population at baseline.
Risk of cancer and death, cumulative incidence functions
and causes of death
During mean follow-up, 11,375 (9.3%) of the MI patients
developed first-time cancer and 65,225 (53.3%) died,
whereas 372,397 (13.0%) individuals in the reference
population developed cancer and 753,767 (26.3%) died
(Fig. 1). The IRs of cancer and death increased with
advancing age in both populations, but both cancer and
death were more frequent among MI patients in all age
groups, as well as time following MI (Fig. 2 and
Additional file 1: Figure S1A-C). The highest incidences
of death and cancer were observed during the first year
following MI (Additional file 1: Figure S1A-C), but the
incidence of death was higher than cancer, especially
during the first year after an MI. In the reference popu-
lation, the incidence of cancer was comparable to the
incidences of death, except in the oldest individuals, in
whom risk of death was higher than cancer risk (Fig. 2
and Additional file 1: Figure S1A-C). In MI patients,
lung and prostate cancer were the most common sub-
types of cancer, whereas breast cancer was the most
common cancer in the reference population (Additional
file 2: Table S1).
According to age and continuous time since MI, the
cumulative incidence of cancer increased steadily,
although the incidence rate for the oldest age group
decreased over time and crossed the incidence rate of
55–69 year olds after approximately 7 years of follow-up
(Additional file 1: Figure S2). In all age groups, cumula-
tive incidence of death showed high mortality right after
diagnosis of MI (Additional file 1: Figure S3).
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Relative risk of cancer
The highest risk of overall cancer was observed during
the first month after an MI diagnosis with a subsequent
decrease, reaching a somewhat constant level 6 months
following a first time MI diagnosis (Additional file 2:
Table S2A-B).
MI patients had significantly increased risks of
overall, lung and lower urinary tract cancer after ad-
justment for age, sex and calendar year (Fig. 3a), also
after additional adjustment for diabetes, hypertension,
dyslipidemia, chronic obstructive pulmonary disease
and socioeconomic status (Fig. 3b). When further
excluding the first 6 months following an MI, only lower
urinary tract cancer remained significantly increased
among MI patients (Fig. 3c). The risks of overall, lung,
colorectal and lower urinary tract cancer were highest in
the youngest age group (30–54) of MI patients and
decreased with advancing age (55–69 years of age and 70–
99 years of age, Additional file 2: Table S3A-C). Women
were generally at increased risk of cancer compared to
men (p for interaction < 0,0001), and the difference in
risk of cancer attenuated after adjustment for comor-
bidities (Additional file 2: Table S4).
Discussion
Major findings
In this nationwide study, we observed that an MI is only
modest associated with an increased risk of cancer after
adjustment for traditional confounders, mutual risk fac-
tors and comorbidities and it became insignificant after
exclusion of the first 6 months after the MI, suggesting
that mutual risk factors, occult cancers and surveillance
bias explain the increased incidence of cancer in the MI
population.
Incidence rates of cancer and death
The observation of increased cancer risk in the years fol-
lowing a diagnosis of MI is in accordance with previous
studies [5, 6, 14–16] and age-stratified analyses did not
change this observation. This finding may in part reflect
surveillance bias and occult cancers in the early phase
(0–1 year) after an MI, however, the surviving MI
patients continued their lives at increased cancer risk
compared with the reference population. It should be
noted that since patients with a previous cancer diagno-
sis were excluded, end-stage cancer patients did not ex-
plain these findings. The cumulative incidence of cancer
Fig. 1 Flow chart of the study population. MI Myocardial infarction
Table 1 Baseline characteristics
Reference population
in 01 January 1996
MI population
at time of MI
n 2,871,168 122,275
No. of person-years 40,038,194 594,061
Female, n (%) 1,493,795 (52.0) 47,501 (38.8)
Median age (IQR)
Men 49.5 (39.5–61.3) 59.2 (49.5–69.5)
Women 51.7 (41.0–66.4) 68.5 (58.1–76.0)
Comorbidity, n (%)
COPD 37,001 (1.3) 11,032 (9.0)
Dyslipidemia 13,794 (0.5) 21,408 (17.6)
Diabetes mellitus 58,495 (2.0) 15,154 (12.4)
Hypertension 116,249 (4.1) 17,187 (14.1)
Medication, n (%)
Aspirin 121,922 (4.3) 44,145 (36.1)
Renin-angiotensin inhibitors 92,811 (3.2) 37,562 (30.7)
Calcium channel blockers 124,708 (4.3) 36,787 (30,1)
Beta blockers 121,792 (4.2) 33,771 (27.6)
Statins 10,638 (0.4) 21,200 (17.3)
MI =myocardial infarction, IQR = interquartile range. COPD = chronic obstructive
pulmonary disease
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after an MI continued to increase over time in the two
youngest age groups confirming that younger long-term
survivors from an MI have an increased risk of cancer
despite an increased risk of death compared to the refer-
ence population. The risk of cancer after an MI is, there-
fore, highest the first year after an MI, but despite a high
risk of death, cancer continues to develop over time. A
high mortality risk in the early years after an MI is,
therefore, a larger clinical challenge than development of
comorbidities such as cancer, and more research in
mode of death and development of cardiovascular drugs
for secondary prevention of cardiovascular death is still
warranted.
Relative risks of cancer (Poisson regression analyses)
The associations between a history of MI and cancer risk
were largely attenuated following adjustment for comor-
bidities and became insignificant after adjustment for
the first 6 months post-MI, suggesting that mutual risk
factors, occult cancers and surveillance bias, and not a
shared pathogenesis (e.g. oxidative stress between
atherosclerosis and cancer), may explain the increased
incidence of cancer after an MI. This is supported by the
fact that the two smoke related cancers, lung and lower
urinary tract cancer, seemed to be associated with MI
before adjustment for comorbidities. Nonetheless, risk of
lower urinary tract cancers remained significantly
increased after full adjustment, which can likely be
explained by unmeasured and residual confounding, e.g.
history of tobacco. Based on our data, it is, however,
difficult to explain the exact mechanism(s) why the associ-
ation became insignificant after adjustment for comor-
bidities, but it may be speculated that environmental
factors like tobacco and alcohol [25], unhealthy diet,
shared genetic susceptibility, inflammation [26, 27]
and medication play a role, since these mechanisms
are reflected in the confounders adjusted for in the
analyses. Furthermore, a previous study observed an
increased incidence of cancer after MI in patients
with heart failure compared to those without heart
failure after MI [28]. Thus, eliminating comorbidities
may have eliminated the sicker patients more prone
to post-MI heart failure. Lastly, it should be men-
tioned that analyses in cumulative incidence showed
that cancer may be even less of a concern in absolute
measures than indicated by relative measures.
Fig. 2 Incidence of cancer and death stratified by age group in the MI and reference population. 95% Confidence intervals from left to right:
(3.8–4.7), (19.8–21.7), (2.8–2.9), (2.9–3.0), (13.2–14.2), (41.0–42.7), (10.5–10.6), (11.3–11.4), (26.5–27.7), (176.6–179.6), (22.2–22.4), (64.6–64.9), (18.8–19.5),
(105.2–106.9), (9.3–9.3), (18.2–18.3). MI = Myocardial infarction
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The strong associations between an MI and a new
onset cancer in the first 6 months, especially the first
month, even after adjustment for comorbidities com-
pared to the remaining follow-up, indicate that our
observations are likely explained by surveillance bias.
Being in contact with the healthcare system increases
the chance of early detection of cancer due to intensive
clinical evaluation, a large number of tests and increased
reporting of non-cardiac symptoms. Platelet inhibition
may also induce bleeding in clinically silent cancers post
MI, requiring further diagnostic testing. Another explan-
ation to this association could be occult cancers during
time of MI, as they provide a prothrombotic state [12]
that may increase the risk of MI [13] and other arterial
thrombotic diseases [29].
Radiation and new onset cancer after an MI
One could speculate that MI patients are more ex-
posed to radiation through percutaneous coronary in-
terventions and other procedures, which could affect
our results. If so, we would have expected increasing
risk of developing cancers in the chest, such as lung
and breast cancer, in the years following MI. In this
study, breast cancer showed a non-significantly in-
creased risk of cancer only 10–17 years following MI.
However, after the first year following an MI, a
history of an MI was consistently associated with in-
creased risk of lung and lower urinary tract cancers,
suggesting that smoking may be the main explanation
to this observation.
Strengths and limitations
The major strengths of this nationwide study include the
diminished risk of selection bias, the minimal loss of
follow-up ensured by the comprehensive Danish regis-
tries, and the large sample size of almost 3 million
people with up to 17 years of follow-up, which gave us
the unique possibility to study the risk of overall and
subtypes of cancer in MI patients. Conversely, given the
observational nature of this study, several important
limitations need to be addressed.
The primary limitation was the risk of unmeasured
and residual confounding by variables not available to us
from the administrative registries, namely smoking, alco-
hol consumption, body mass index, physical activity
level, diet and metabolic abnormalities not requiring
medication. Further studies are needed to discover the
effect of these common risk factors on the risk of cancer
in MI patients. Secondly, surveillance bias is likely to
have affected our results, thus being in contact with the
healthcare system increases the chance of diagnosing a
cancer. Thirdly, our results rely on discharge diagnoses
on cancer and MI from hospitals. Nonetheless, although
minor misclassifications exist in the NPR, especially
when the coding practice is unclear, the misclassifica-
tions are non-systematic and do not influence the overall
validity of the NPR data [19, 30–32]. Both the MI and
cancer diagnoses have high predictive values and a high
sensitivity. Theoretically some cases of an MI or a can-
cer may have been overlooked which may have biased
our results toward zero. However, we do not think that
misclassification of MI or cancer explain our results
since our results are in accordance with previous studies
on the association between atherosclerosis and incident
cancer [14]. Whether the observed cancers within the
first year after the MI are early stage cancers without
impact on e.g. length of life cannot be addressed based
on the present analyses. However, reverse causality may
be a limitation given the higher risk of cancer in the first
year and co-occurrence as seen in Fig. 1. Additionally,
cancer events were primarily identified from NPR with
supplement from the Danish Register of Causes of
Death. We did not have access to The Danish Cancer
Registry or the Danish Pathology Registry, and thus our
study may underestimate the number of cancer events.
However, the number is considered low, since the
Danish Pathology Registry forwards information to the
Danish Register of Causes of Death. Further studies are
needed to examine whether more advanced cancers are
more or less associated with MI. Furthermore, the
definitions of some of the comorbidities in our data rely
on information poorly registered in the registries. To
accommodate this, in accordance with previous work,
prescribed medications were used as proxies to define dia-
betes mellitus, hypertension and dyslipidemia [20, 21].
Lastly, the majority of the Danish population is white, so
our results are not generalizable to non-white people.
(See figure on previous page.)
Fig. 3 a Incidence rate ratios of overall cancer and selected subtypes of cancer associated with a myocardial infarction. Analyses are adjusted for
age, sex and calendar year: MI = myocardial infarction, LUT = lower urinary tract, n = number of cancers, N = number of persons. b. Incidence rate
ratios of overall cancer and selected subtypes of cancer associated with a myocardial infarction. Analyses are adjusted for age, sex, calendar year,
hypertension, dyslipidemia, diabetes, chronic obstructive pulmonary disease and socioeconomic status. MI =myocardial infarction, LUT = lower
urinary tract, n = number of cancers, N = number of persons c. Incidence rate ratios of overall cancer and selected subtypes of cancer associated
with a myocardial infarction 6 months – 17 years post-MI. Analyses are adjusted for age, sex, calendar year, hypertension, dyslipidemia, diabetes,
chronic obstructive pulmonary disease and socioeconomic status. MI =myocardial infarction, LUT = lower urinary tract, n = number of cancers,
N = number of persons
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Conclusions
This study suggests that the increased incidence of
cancer among patients with myocardial infarction may
be due mutual risk factors, occult cancers and increased
surveillance rather than an independent association. Fur-
thermore, death is still a larger clinical challenge at all
ages, especially by cardiac death rather than cancer in
the early years after the myocardial infarction. Cardiolo-
gists and general practitioners should be aware of signs
and symptoms of cancer in myocardial infarction survi-
vors, but focus on secondary prevention and manage-
ment after MI to reduce mortality is warranted.
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